News & Blog

Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson’s Disease

Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc.

MEC Newsletter: Q2 2025 – The Future of Precision Regenerative Medicine: MEC’s Investments in Induced Pluripotent Stem Cell Therapies

Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity

GC Therapeutics Advances Cell Programming with Systematic Discovery of Transcription Factor Combinations

PRO-101: study design and interim results from a Phase 1 study to evaluate the safety, tolerability, PK, and PD of prosetin in ALS

MEC Newsletter: Q1 2025 – Biotech’s Next Chapter: What We Learned at Stanford—and Why Unity Is the New Imperative

Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease

Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting

SonoThera™ to Present New Data at ASGCT 2025 Demonstrating the Potential of Genetic Medicine Using Targeted, Ultrasound-Mediated Delivery in Treating Duchenne Muscular Dystrophy and Hemophilia A